JP2007526313A - カルボニル捕捉剤によって細胞死を誘発する方法 - Google Patents
カルボニル捕捉剤によって細胞死を誘発する方法 Download PDFInfo
- Publication number
- JP2007526313A JP2007526313A JP2007501872A JP2007501872A JP2007526313A JP 2007526313 A JP2007526313 A JP 2007526313A JP 2007501872 A JP2007501872 A JP 2007501872A JP 2007501872 A JP2007501872 A JP 2007501872A JP 2007526313 A JP2007526313 A JP 2007526313A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- penicillamine
- carbonyl
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title claims abstract description 34
- 230000030833 cell death Effects 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims description 14
- 230000001939 inductive effect Effects 0.000 title claims description 6
- 230000002159 abnormal effect Effects 0.000 claims abstract description 9
- 230000034994 death Effects 0.000 claims abstract description 6
- 231100000517 death Toxicity 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 53
- 201000001441 melanoma Diseases 0.000 claims description 29
- 239000002516 radical scavenger Substances 0.000 claims description 24
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- FIXGPNLTDAUQQF-BYPYZUCNSA-N methyl (2s)-2-amino-3-methyl-3-sulfanylbutanoate Chemical compound COC(=O)[C@H](N)C(C)(C)S FIXGPNLTDAUQQF-BYPYZUCNSA-N 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 210000002510 keratinocyte Anatomy 0.000 claims description 4
- KAVACCZQLOLHTO-INEUFUBQSA-N (2r,3r)-2-amino-3-methyl-3-sulfanylpentanoic acid Chemical compound CC[C@@](C)(S)[C@H](N)C(O)=O KAVACCZQLOLHTO-INEUFUBQSA-N 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000001133 acceleration Effects 0.000 abstract 1
- 230000005775 apoptotic pathway Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 34
- 229960001639 penicillamine Drugs 0.000 description 31
- 230000006907 apoptotic process Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 230000003211 malignant effect Effects 0.000 description 14
- MNNBCKASUFBXCO-YFKPBYRVSA-N N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)S MNNBCKASUFBXCO-YFKPBYRVSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 208000030381 cutaneous melanoma Diseases 0.000 description 5
- 210000001700 mitochondrial membrane Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 4
- POYPKGFSZHXASD-WDSKDSINSA-N D-penicillamine disulfide Chemical compound OC(=O)[C@H](N)C(C)(C)SSC(C)(C)[C@@H](N)C(O)=O POYPKGFSZHXASD-WDSKDSINSA-N 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 208000009621 actinic keratosis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000006882 induction of apoptosis Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- WKYPQDXTDPCZHT-ROLXFIACSA-N (2r)-2-amino-4-methyl-3-sulfanylpentanoic acid Chemical compound CC(C)C(S)[C@H](N)C(O)=O WKYPQDXTDPCZHT-ROLXFIACSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 208000023514 Barrett esophagus Diseases 0.000 description 2
- 208000023665 Barrett oesophagus Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004989 dicarbonyl group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YYUZUAHZZCMKSF-WHFBIAKZSA-N (2s,3s)-3-methyl-2-(sulfanylamino)pentanoic acid Chemical compound CC[C@H](C)[C@H](NS)C(O)=O YYUZUAHZZCMKSF-WHFBIAKZSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Storage Of Fruits Or Vegetables (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本出願は、2004年3月2日に出願され、ここにその全体を参考文献として合体させる出願番号60/549,805の一部継続出願である。
本発明は、ジカルボニル捕捉剤などのカルボニル捕捉剤を使用して、細胞死を誘発する方法に関する。
非メラノーマ疾患や、メラノーマ皮膚がん等を含む皮膚疾患の増加については十分に記録されており、前悪性又は悪性段階の皮膚がんのための有効な治療法が依然として欠如していることも同様に十分に記録されている。
図1は、ネズミ(B16)及びヒト(G−361,A−375,LOX)細胞ラインの悪性メラノーマ細胞ラインに対するD−ペニシラミンを使用したアポトーシス誘発の比較を示している。この図において、“C”は、対照を示し、 “P”はD−ペニシラミンでの治療を示す。
例1
この例は、3−メルカプト−D−バリン(“D−ペニシラミン”)が悪性細胞ラインのアポトーシスを誘発したことを示す実験を示すものである。
これらの実験では、前悪性不死化ヒトケラチン生成細胞又は”“HaCaT”細胞に対して、D−ペニシラミンを、12.5mMの濃度で添加し、曝露を24時間連続させた。
このセットの実験は、D−ペニシラミンと、それのより親油性の強い誘導体である、D−ペニシラミンメチルエステルの両方を利用した。
その他のガン、特に、上皮ガンに対する前記化合物の効能を測定した。ヒトHeLa頚部腺癌細胞を使用し、10mMのD−ペニシラミンと、25mMのアミノグアニジンでテストした。これらを、カルボニル捕捉剤として作用しない、N−アセチル−D−ペニシラミンでテストした。
3−メチル−3−エチル−L−システイン(メルカプトイソロイシン、又は“MEC”)は、前にテストしたよりも親油性の高いカルボニル捕捉剤である。局所投与システムでは、高い親油性が望ましいので、この化合物をテストすることが興味深かった。
これらの実験は、構造/作用関連性が存在するか否かを調べるために構成された。換言すると、抗酸化物質としてではなく、カルボニル捕捉剤としての活性が抗がん活性のための重要であるか否かを調べることに注目した。
ガンの治療におけるカルボニル捕捉剤の治療的潜在性をこれらの実験で証明した。
これらの実験は、前記カルボニル捕捉剤処理が誘発した優先性アポトーシスがミトコンドリア膜電位差“ΔΨm”の脱分極によって起こることを証明するものである。リアーズ(Reers)他, Biochemistry 30 (18): 4480-6 (1991)に従って、電位差測定色素(potentiometric)JC−1を使用した。10mMのD−ペニシラミンを培地に添加した24時間後に前記色素を加えた。RCS前処理として、5mMのフェニルグリオキサルを15分間使用し、その後、PBSで洗浄し、新しい培地を添加した。
Claims (10)
- 異常細胞において細胞死を誘発又は加速させる方法であって、前記異常細胞に対して、D−ペニシラミンメチルエステル、アミノグアニジン、及び3−メルカプトイソロイシンから成るグループから選択されるカルボニル捕捉剤を前記異常細胞の死を誘発又は加速させるのに十分な量の投与する工程を含む方法。
- 前記異常細胞が、皮膚細胞である請求項1に記載の方法。
- 前記異常細胞が、癌細胞又は前癌細胞である請求項1に記載の方法。
- 前記癌細胞が、扁平上皮癌細胞、上皮癌細胞、メラノーマ細胞又は腺癌細胞である請求項3に記載の方法。
- 前記カルボニル捕捉剤を局所的に投与する、請求項1に記載の方法。
- 前記前癌細胞が、ケラチン生成細胞である請求項3に記載の方法。
- 前記カルボニル捕捉剤をヒトに投与する工程を含む請求項1に記載の方法。
- 前記カルボニル捕捉剤が、D−ペニシラミンメチルエステルである請求項1に記載の方法。
- 前記カルボニル捕捉剤が、アミノグアニジンである請求項1に記載の方法。
- 前記カルボニル捕捉剤が、3−メルカプトイソロイシンである請求項1に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54980504P | 2004-03-02 | 2004-03-02 | |
PCT/US2005/006288 WO2005084659A1 (en) | 2004-03-02 | 2005-03-01 | Method for inducing cell death with carbonyl scavengers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007526313A true JP2007526313A (ja) | 2007-09-13 |
JP4642837B2 JP4642837B2 (ja) | 2011-03-02 |
Family
ID=34919540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501872A Expired - Fee Related JP4642837B2 (ja) | 2004-03-02 | 2005-03-01 | カルボニル捕捉剤によって細胞死を誘発する方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US7217739B2 (ja) |
EP (1) | EP1720538B1 (ja) |
JP (1) | JP4642837B2 (ja) |
CN (1) | CN100522153C (ja) |
AT (1) | ATE413871T1 (ja) |
AU (1) | AU2005219390B2 (ja) |
CA (1) | CA2557666C (ja) |
DE (1) | DE602005010980D1 (ja) |
DK (1) | DK1720538T3 (ja) |
ES (1) | ES2317214T3 (ja) |
HK (1) | HK1102768A1 (ja) |
HR (1) | HRP20080599T3 (ja) |
PL (1) | PL1720538T3 (ja) |
PT (1) | PT1720538E (ja) |
RS (1) | RS50632B (ja) |
SI (1) | SI1720538T1 (ja) |
WO (1) | WO2005084659A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063229A2 (en) * | 2006-05-12 | 2008-05-29 | Livingston James A | Enzymatic debridement therapy for abnormal cell proliferation |
RU2447848C2 (ru) * | 2010-07-26 | 2012-04-20 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ профилактики полостных спаек |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4762705A (en) * | 1981-11-10 | 1988-08-09 | Adolf W. Schwimmer | Cancer therapy with interferon |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6093745A (en) * | 1997-11-25 | 2000-07-25 | Psorx, L.L.C. | Methods and composition for treating skin proliferative diseases |
US6811788B2 (en) * | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US6417235B2 (en) * | 2000-04-14 | 2002-07-09 | University Of Kentucky Research Foundation | Method and use of α-amino-β-mercapto-ethane derivatives as dicarbonyl scavengers for treatment of conditions resulting from protein, lipid, and DNA damage |
WO2001079842A2 (en) * | 2000-04-14 | 2001-10-25 | Niadyne Corporation | Method for identifying regulators of protein-age formation |
US6723168B2 (en) * | 2001-06-20 | 2004-04-20 | Taiwan Semiconductor Manufacturing Co., Ltd. | Spin-coater with self-cleaning cup and method of using |
WO2003004469A1 (en) * | 2001-07-02 | 2003-01-16 | Dabur Research Foundation | Anticancer activity of imino acid conjugates of methylglyoxal |
US7071164B2 (en) * | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
-
2005
- 2005-03-01 CA CA2557666A patent/CA2557666C/en not_active Expired - Fee Related
- 2005-03-01 DE DE602005010980T patent/DE602005010980D1/de active Active
- 2005-03-01 PT PT05723942T patent/PT1720538E/pt unknown
- 2005-03-01 DK DK05723942T patent/DK1720538T3/da active
- 2005-03-01 US US11/069,292 patent/US7217739B2/en active Active
- 2005-03-01 ES ES05723942T patent/ES2317214T3/es active Active
- 2005-03-01 SI SI200530571T patent/SI1720538T1/sl unknown
- 2005-03-01 PL PL05723942T patent/PL1720538T3/pl unknown
- 2005-03-01 AU AU2005219390A patent/AU2005219390B2/en not_active Ceased
- 2005-03-01 CN CNB2005800065503A patent/CN100522153C/zh not_active Expired - Fee Related
- 2005-03-01 EP EP05723942A patent/EP1720538B1/en active Active
- 2005-03-01 JP JP2007501872A patent/JP4642837B2/ja not_active Expired - Fee Related
- 2005-03-01 RS RSP-2008/0557A patent/RS50632B/sr unknown
- 2005-03-01 WO PCT/US2005/006288 patent/WO2005084659A1/en active Application Filing
- 2005-03-01 AT AT05723942T patent/ATE413871T1/de active
-
2007
- 2007-10-16 HK HK07111130A patent/HK1102768A1/xx not_active IP Right Cessation
-
2008
- 2008-12-17 HR HR20080599T patent/HRP20080599T3/xx unknown
Non-Patent Citations (5)
Title |
---|
JPN6010003982, Salvucci, O. et al., Cancer Research, 2001, Vol. 61, p. 318−326 * |
JPN6010003989, Jeitner, T.M. et al., Cancer Letters, 1996, Vol. 103, p. 85−90 * |
JPN6010003992, Hortelano, S. et al., Molecular Pharmacology, 1997, Vol. 51, p. 414−421 * |
JPN6010037834, Benjamin T. Hourani et al., Laboratory Investigation, 1969, Vol. 21, No. 5, p. 434−438 * |
JPN7010000224, Valente, E. et al., Microbial Pathogenesis, 2000, Vol. 29, p. 345−356 * |
Also Published As
Publication number | Publication date |
---|---|
EP1720538A1 (en) | 2006-11-15 |
PT1720538E (pt) | 2008-12-26 |
EP1720538B1 (en) | 2008-11-12 |
HRP20080599T3 (en) | 2009-01-31 |
WO2005084659A1 (en) | 2005-09-15 |
PL1720538T3 (pl) | 2009-04-30 |
ES2317214T3 (es) | 2009-04-16 |
CN100522153C (zh) | 2009-08-05 |
AU2005219390A1 (en) | 2005-09-15 |
AU2005219390B2 (en) | 2008-05-01 |
RS50632B (sr) | 2010-06-30 |
HK1102768A1 (en) | 2007-12-07 |
SI1720538T1 (sl) | 2009-04-30 |
US7217739B2 (en) | 2007-05-15 |
US20050197400A1 (en) | 2005-09-08 |
ATE413871T1 (de) | 2008-11-15 |
CA2557666C (en) | 2010-04-27 |
EP1720538A4 (en) | 2007-04-11 |
DE602005010980D1 (de) | 2008-12-24 |
DK1720538T3 (da) | 2009-01-19 |
CA2557666A1 (en) | 2005-09-15 |
JP4642837B2 (ja) | 2011-03-02 |
CN1964710A (zh) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7307107B2 (ja) | スキンホワイトニング(色を薄くする)化合物系列 | |
AU2003230972B2 (en) | 3-deoxyglucosone and skin | |
DK2152256T3 (en) | TELOMERASEAKTIVERENDE compounds and methods of use thereof | |
EP1701938A1 (fr) | Composes derives de 1,3-diphenylprop-2-en-1-one, preparation et utilisations | |
KR20050019818A (ko) | 치환된 1,3-디페닐프로프-2-엔-1-온 유도체에 기초한조성물, 이의 제조 및 용도 | |
EP2744487B1 (en) | No- and h2s- releasing compounds | |
EP3562830A1 (en) | Hydroxybenzoic acid derivatives, methods and uses thereof | |
KR101877575B1 (ko) | 색소 침착 예방 또는 개선제 | |
EP1328263B1 (en) | Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells | |
JP4642837B2 (ja) | カルボニル捕捉剤によって細胞死を誘発する方法 | |
EP1553933B1 (fr) | Medicament comprenant une thiouree pour son utilisation en tant que depigmentant ou agent antimutagene et anticarcinogene | |
FR3050455B1 (fr) | Derives amides des acides polycafeoylquiniques, procede de preparation et utilisations | |
JP7051843B2 (ja) | デンドロビウムベ-スの材料を含有する皮膚保護組成物 | |
JP2019218343A (ja) | 新規の化合物、これを含む化粧料組成物および薬学的組成物 | |
FR2864956A1 (fr) | Compose derive de 1,3-diphenylprop-2-en-1-one, preparation et utilisations | |
CA2888379A1 (fr) | Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer | |
US10351500B2 (en) | Method of using of dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants as antimicrobial agents | |
JP7320808B2 (ja) | 皮膚外用剤 | |
JP4279523B2 (ja) | チロシナーゼ阻害剤 | |
WO2022133011A1 (en) | Compositions for targeting receptor for advanced glycation end-products (rage) in a chronic inflammatory condition | |
CN110698328A (zh) | 二氢白藜芦醇或其芪类衍生物和/或化学变体作为抗微生物剂的使用方法 | |
JP2013001658A (ja) | 肌荒れ予防又は改善剤 | |
WO2014162106A1 (fr) | Nouveaux derives de chalcone presentant une activite anti-allergique | |
JPWO2014174583A1 (ja) | 新規美白剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101007 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101104 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4642837 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131210 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |